186 related articles for article (PubMed ID: 16636810)
1. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice.
Sirova M; Strohalm J; Subr V; Plocova D; Rossmann P; Mrkvan T; Ulbrich K; Rihova B
Cancer Immunol Immunother; 2007 Jan; 56(1):35-47. PubMed ID: 16636810
[TBL] [Abstract][Full Text] [Related]
2. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
Shamay Y; Golan M; Tyomkin D; David A
J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
[TBL] [Abstract][Full Text] [Related]
3. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
4. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
5. Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):375-83. PubMed ID: 8866656
[TBL] [Abstract][Full Text] [Related]
6. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B
Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609
[TBL] [Abstract][Full Text] [Related]
7. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
8. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657
[TBL] [Abstract][Full Text] [Related]
9. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
Etrych T; Jelínková M; Ríhová B; Ulbrich K
J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells.
Kovar L; Etrych T; Kabesova M; Subr V; Vetvicka D; Hovorka O; Strohalm J; Sklenar J; Chytil P; Ulbrich K; Rihova B
Tumour Biol; 2010 Aug; 31(4):233-42. PubMed ID: 20556593
[TBL] [Abstract][Full Text] [Related]
11. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility.
Ríhová B; Srogl J; Jelínková M; Hovorka O; Buresová M; Subr V; Ulbrich K
Ann N Y Acad Sci; 1997 Dec; 831():57-71. PubMed ID: 9616702
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice.
Shiah JG; Dvorák M; Kopecková P; Sun Y; Peterson CM; Kopecek J
Eur J Cancer; 2001 Jan; 37(1):131-9. PubMed ID: 11165140
[TBL] [Abstract][Full Text] [Related]
13. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
14. A novel α
Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z
J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244
[TBL] [Abstract][Full Text] [Related]
15. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
16. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.
Seymour LW; Ulbrich K; Steyger PS; Brereton M; Subr V; Strohalm J; Duncan R
Br J Cancer; 1994 Oct; 70(4):636-41. PubMed ID: 7917909
[TBL] [Abstract][Full Text] [Related]
17. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.
Sirova M; Mrkvan T; Etrych T; Chytil P; Rossmann P; Ibrahimova M; Kovar L; Ulbrich K; Rihova B
Pharm Res; 2010 Jan; 27(1):200-8. PubMed ID: 19894105
[TBL] [Abstract][Full Text] [Related]
19. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
[TBL] [Abstract][Full Text] [Related]
20. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
